What is the appropriate evaluation and treatment approach for a patient with euvolemic hyponatremia?

Euvolemic Hyponatremia: Evaluation and Treatment

For euvolemic hyponatremia, first rule out thyroid disease, adrenal insufficiency, and medication causes (especially thiazides), then treat SIADH—the most common cause—with fluid restriction (500 mL/day) combined with increased solute intake, advancing to urea or tolvaptan when fluid restriction fails. 1, 2

Diagnostic Evaluation

When serum sodium drops below 135 mEq/L (or 131 mmol/L per neurosurgical guidelines), obtain:

• Serum and urine osmolality
• Urine sodium and electrolytes
• Serum uric acid
• Clinical volume assessment 3

Do not obtain ADH or natriuretic peptide levels—they have limited diagnostic value and conflicting data. 3

Confirming Euvolemia and SIADH

For SIADH diagnosis, you need:

• Low serum osmolality
• Inappropriately elevated urine osmolality (>100 mOsm/L)
• Elevated urine sodium (typically >40 mEq/L)
• Clinical euvolemia 4

Critical exclusions before diagnosing SIADH:

• Screen for thiazide diuretics
• Rule out hypothyroidism
• Rule out adrenal insufficiency (hypocortisolism)
• Exclude polydipsia 3, 4

Clinical Mimics to Consider

In specific populations, consider:

• Cerebral salt wasting (neurosurgical patients)
• Reset osmostat (chronic conditions) 4

Treatment Algorithm

Step 1: Assess Symptom Severity and Chronicity

Severely symptomatic (seizures, coma, obtundation, cardiorespiratory distress):

• This is a medical emergency regardless of chronicity
• Use 3% hypertonic saline as 100-150 mL IV bolus 1, 2
• Target: increase sodium by 4-6 mEq/L within 1-2 hours
• Maximum correction limit: 8-10 mEq/L in first 24 hours 3, 2
• If 6 mEq/L corrected in 6 hours, limit additional correction to 2 mEq/L over next 18 hours 3

Asymptomatic or mildly symptomatic chronic hyponatremia:

• Proceed to Step 2

Step 2: First-Line Therapy for SIADH

Initiate fluid restriction at 500 mL/day combined with:

• Adequate solute intake (increased salt and protein)
• Adjust restriction based on sodium response 1, 5

Important caveat: Nearly half of SIADH patients fail fluid restriction as first-line therapy 1. Monitor closely and advance to second-line therapy if no improvement within 48-72 hours.

Step 3: Second-Line Therapy When Fluid Restriction Fails

Choose between urea or tolvaptan (both considered equally effective second-line options):

Urea:

• Very effective and safe
• Dose: typically 15-30 g/day divided
• Drawbacks: poor palatability, gastric intolerance 2, 5

Tolvaptan (vaptan):

• Effective for euvolemic and hypervolemic hyponatremia
• Drawbacks: risk of overly rapid correction, increased thirst, cost 2, 5
• Requires close monitoring with readiness to administer hypotonic fluids or desmopressin for overcorrection 1

The choice between these depends on patient tolerance, monitoring capability, and availability. Urea is preferred when close monitoring is limited; tolvaptan when gastric tolerance is poor but intensive monitoring is available. 1, 5

Critical Pitfalls to Avoid

Never use 0.9% normal saline in SIADH treatment:

• Acts as hypertonic solution in hyponatremic patients
• Causes rapid fluctuations: initial rapid correction (risking osmotic demyelination) followed by post-infusion worsening 4

Chronic hyponatremia must not be rapidly corrected:

• Overly rapid correction causes osmotic demyelination syndrome (ODS)
• ODS results in parkinsonism, quadriparesis, or death 3, 2
• Occurs in 4.5-28% when correction limits are exceeded 2

For high-risk patients receiving hypertonic saline:

• Administer parenteral desmopressin simultaneously to prevent overly rapid correction 4
• Monitor sodium every 2-4 hours during active correction 1

Special Populations

Subarachnoid hemorrhage patients:

• Treat even when sodium is 131-135 mmol/L (higher threshold than general population) 3

Neurosurgical patients:

• Higher index of suspicion for cerebral salt wasting versus SIADH
• Volume status assessment is critical to differentiate 3